- Home
- RCKT vs LBRX Comparison
RCKT vs LBRX Comparison
Compare RCKT & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCKT | LBRX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | 202 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 534.2M | 602.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RCKT | LBRX |
|---|---|---|
| Price | $4.87 | $26.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 3 |
| Target Price | $29.65 | ★ $49.00 |
| AVG Volume (30 Days) | ★ 2.9M | 205.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $97.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.19 | $13.40 |
| 52 Week High | $8.80 | $26.65 |
Technical Indicators
Market Signals| Indicator | RCKT | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.97 | 67.41 |
| Support Level | $2.99 | $22.34 |
| Resistance Level | $5.34 | N/A |
| Average True Range (ATR) | 0.38 | 1.28 |
| MACD | -0.00 | 0.13 |
| Stochastic Oscillator | 51.16 | 82.90 |
Price Performance
Historical ComparisonAbout RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.